Abstract
Cerecor will acquire rare-disease-drug-focused Ichorion Therapeutics in an all-stock deal worth $26.6 million. Ichorion is developing treatments for rare metabolic disorders, including several substrate replacement therapies. In addition to expanding its pipeline in neurology and pediatric orphan diseases, Cerecor says, the deal adds two drug candidates eligible for rare pediatric disease priority review vouchers, transferable assets that shorten FDA’s review time.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have